Picture of Dr. John R. Gordon

Dr. John R. Gordon BSc, PhD Professor Respirology, Critical Care and Sleep Medicine

Rm 2D30.8 (Box 3), HSc D wing

Research Area(s)

  • Respiratory Immunology and Inflammation (pathogenesis)
  • Allergy
  • Asthma
  • Immunotherapeutics
  • Dendritic cells
  • Regulatory T cells
  • Th2 cells
  • Neutrophils


Dr. John Gordon received his PhD in immunopathology from the University of Saskatchewan in 1984.  He did post-doctoral fellowships at the National Institute for Medical Research at Mill Hill, UK (1984-87) and the Department of Pathology at Harvard Medical School (1987-88), then worked as an Instructor in the Department of Pathology at the latter institution (1988-91).  He returned to the University of Saskatchewan in 1991 as an Associate Professor in the Department of Veterinary Microbiology.  In 2007 he moved to the Department of Medicine as the Director of the Canadian Centre for Health and Safety in Agriculture (2007-12), after which he served as Acting Associate Dean Research for the College of Medicine (2012-13).  He is presently a Professor in the Division of Respirology, Critical Care and Sleep Medicine, Department of Medicine.

Dr. Gordon’s laboratory focus is immunotherapeutics in the context of allergic and other inflammatory diseases.  They have developed regulatory dendritic cell protocols to reverse asthma and food allergen sensitivity in animal models and have shown that these approaches are relevant also to human disease.  They are presently moving to translate regulatory dendritic cell immunotherapies into the clinic. Their lab also patented a series of anti-inflammatory drugs that attenuate neutrophilic inflammation in an array of animal models, but they have more recently shown that these same agents potently antagonize the growth, metastasis and development of chemotherapeutic resistance in multiple tumours.  Dr. Gordon’s lab has been funded for >25 years by the Canadian Institutes for Health Research (CIHR), but is also funded by the Natural Sciences and Engineering Research Council (NSERC) of Canada, the Canadian Foundation for Innovation, the Canadian Cystic Fibrosis Foundation (CCFF), the Saskatchewan Health Research Foundation (SHRF) and AllerGen NCE.

Dr. Gordon devotes considerable time and energy to mentoring trainees within his own laboratory. He was also a co-Leader of the SHRF Airways Research Group and the Scientific Director of a multinational CIHR Strategic Training Program in Health Research.  He is the Vice-president of the Canadian Society for Immunology, and has served on the Boards, management or review committees of the Gairdner Foundation, AllerGen NCE and the CIHR Immunol & Transplantation grant panel among others. 

Current Position:

  • Professor, Division of Respirology, Critical Care & Sleep Medicine, Department of Medicine, University of Saskatchewan, Saskatoon. 2007-present


  • PhD, University of Saskatchewan, 1984 (Immunopathology)
  • B.Sc., University of Saskatchewan, 1977 (Zoology)


  • Professor, Division of Respirology, Critical Care & Sleep Medicine, Department of Medicine, University of Saskatchewan. 2007-Present
  • Acting Associate Dean Research, College of Medicine, University of Saskatchewan. 2012-13
  • Head, Division of Occupational & Rural Health, Department of Medicine, University of Saskatchewan. 2007-12
  • Executive Director, Canadian Centre for Agricultural Medicine, 2007-12
  • Professor, Veterinary Microbiology, University of Saskatchewan, 1997-2007
  • Visiting Professor, Pulmonary Research Group, University of Alberta. Jan-June, 2003
  • Associate Professor, Veterinary Microbiology, University of Saskatchewan. 1991-'97
  • Instructor in Pathology, Dept Pathology, Harvard Medical School, Boston. 1988-91
  • Research Fellow, Dept. Pathology, Harvard Medical School, Boston, MA.  1987-88
  • Research Fellow, National Institute for Medical Research, Mill Hill, U.K. 1984-87

Memberships in Professional Societies

  • Collegium Internationale Allergologicum, 2008-present
  • Canadian Society of Immunology, March, 1991-present
  • American Association of Immunologists, 1987-present
  • Society for Leukocyte Biology, 2004- (lapsed)
  • Canadian Society for Allergy and Clinical Immunology, 2004-present

Honours, Awards, Distinctions (recent)

  • Saskatchewan Health Research Foundation Career Achievement Award, 2014
  • Distinguished Researcher 2011, University of Saskatchewan.  May, 2011
  • Elected to membership, Collegium Internationale Allergologicum. May, 2008 (global membership cap, 250)
  •  ‘Innovator of the Year’ Award, Sask. Innovation Place, 2007 ($5,000)
  • Pfizer Animal Health Research Excellence Award, 2003 ($1,000)

Clinical Interests

  • Immunotherapeutics
  • Asthma & allergic inflammation
  • Immunopathogenesis
  • Neutrophilic inflammation
  • Lung Immunology

Selected Publications

Impact Summary

h-index (Google Scholar)


Total Citations (Google Scholar)


i10 Index (papers cited more than 10 times) (Google Scholar)



  • Z.E. Gillespie, K. MacKay, M. Sander, B. Trost, W. Dawicki, A. Wickramarathna, J.R. Gordon, I. Kill, J. Bridger, A. Kusalik, J.A. Mitchell, C.H Eskiw. 2016. Rapamycin reduces fibroblast proliferation without causing quiescence and induces STAT5A/B-mediated cytokine production. Nucleus 6:490-506
  • B.J. Connell1, J.R. Gordon, T.M. Saleh. 2015. ELR-CXC chemokine antagonism is neuroprotective in a rat model of ischemic stroke. Neurosci Lett 606:117-22
  • M. Asaduzzaman, A. Nadeem, N. Arizmendi, C. Davidson, H. Nichols, M. Abel, L. Ionescu, L. Puttagunda, B. Thebaud, J.R. Gordon, K. Defea, M. Hollenberg, & H. Vliagoftis. 2015. Functional inhibition of PAR2 alleviates allergen-induced airway hyperresponsiveness and inflammation. Clin Exp Allergy 45:1844-55
  • M. Khan, B. Wang, J. Wei, Y Zhang, Q. Li, X. Luan, J-W. Cheng, J.R. Gordon, F. Li, and H. Liu. 2015. CXCR1/2 antagonism with a CXCL8 analogue CXCL8(3-72)K11R/G31P restricts lung cancer growth by inhibiting tumour cell proliferation and suppressing angiogenesis. Oncotarget 6:21315-27
  • L. Li, M.N. Khan, Q. Li, X. Chen, J. Wei, B. Wang, J.W. Cheng, J.R. Gordon, F. Li. 2015. G31P, CXCR1/2 inhibitor, with cisplatin inhibits the growth of mice hepatocellular carcinoma and mitigates high‑dose cisplatin-induced nephrotoxicity. Oncol Rep 33:751-7
  • D. Schneberger, J.R. Gordon, A.J. Heires, J.D.DeVasure, J.A. Boten, D.J. Romberger, T.A. Wyatt. 2015. CXCR1/CXCR2 antagonist CXCL8(3-74)K11R/G31P blocks lung inflammation in swine barn dust-instilled mice. Pulm Pharmacol Therap 31:55-62
  • S.A. Ballendine, Q. Greba, W. Dawicki, X. Zhang, J.R. Gordon, J.G. Howland. 2015. Behavioral alterations in rat offspring following maternal immune activation and ELR-CXC chemokine receptor antagonism during pregnancy: implications for neurodevelopmental psychiatric disorders. Prog Neuro-psychopharm Biol Psych 57:155-65
  • P. Novakovic, Y.Y. Huang, B. Lockerbie, F. Shahriar, J. Kelly, J.R. Gordon, D.M. Middleton, M.E. Loewen, B.A. Kidney, and E. Simko. 2015. Identification of F4ac-binding proteins of porcine milk fat globule membranes.  Canadian Journal of Veterinary Research 79:120-8
  • J.R. Gordon, Y. Ma, L. Churchman, S.A. Gordon and W. Dawicki.  2014.  Regulatory dendritic cells for immunotherapy in immunologic diseases.  Frontiers in Immunology 5: 7 (12 pp; doi: 10.3389/fimmu.2014.00007) (Invited Review)
  • J. Wei, X Chen, Q Li, J Chen, N Khan, B. Wang, J-W Cheng, JR Gordon and F Li. ELR-CXC chemokine antagonism and cisplatin co-treatment additively reduce H22 hepatoma tumor progression and ameliorate cisplatin-induced nephrotoxicity.  2014.  Oncol. Reports 31:1599-604

Patents (last 5 yr; total, 13)

  • Uses of modified ELR-CXC chemokine G31P to treat cancer. JR Gordon, F Li. 2012, WO Patent 2,012,122,642             
  • High-affinity antagonists of  ELR-CXC chemokines. JR Gordon. 2011, EP Patent 2,021,475  
  • Method of treatment using high-affinity antagonists of ELR-CXC chemokines. JR Gordon. 2011, US Patent 8,039,429  
  • Uses of Modified ELR-CXC Chemokine G31P To Treat Cancer. JR Gordon, F Li. 2011, US Patent App. 13/048,290         
  • Uses of modified ELR-CXC chemokine G31P. JR Gordon. 2010, EP Patent 2,257,303            
  • High-affinity antagonists of ELR-CXC chemokines. JR Gordon, F Li. 2010, US Patent 7,741,434

Research Grants:
Principle Investigator (recent)

  • AllerGen National Centre for Excellence. Development of human dendritic cell immunotherapy for treatment of asthma and allergy. 2015-19. $210,000
  • Saskatchewan Health Research Foundation (SHRF) Collaborative Innovation grant. Cellular immunotherapy for atopic dermatitis and the 'atopic march' to asthma. Co-applicants: D. Lichtenwald, E. Simko & C. Rudulier. 2016-17. $40,000
  • SHRF Collaborative Innovation grant. Optimizing regulatory dendritic cell immunotherapy for asthma. Co-applicants: D. Cockcroft, S. Van den Hurk. 2015-16. $40,000
  • NSERC Discovery grant.  ELR-CXC chemokines in tumour progression. $165,000. 2014-19.
  • CIHR Operating grant.  Regulatory dendritic cell immunotherapy for allergic diseases.  2013-18.  $660,000.
  • AllerGen CIHR National Centre of Excellence. Preventing Severe Reactions - Preclinical Studies.  2012-16.  $235,510
  • SHRF Research Groups (Phase II) operating grant.  Airways Research Group (Project: Impact of air quality on the respiratory health in rural Saskatchewan).  2011-2014.  $360,000 (with matching funds from the UofS)


Co-applicant: Last 4 years

  • T. Harkness, T. Arnason, JR Gordon & G. Groot. SHRF Collaborative Innovation grant. In vivo and in vitro evaluation of patient-derived breast cancer cells for early detection and treatment of drug-resistant tumors. 2015-16. $40,000
  • B. Mazer, A. Clarke, J. Marshall, Y. Asai, M. Ben-Shoshan, S. Elliott, C. Piccirillo, A Sanford. GET-FACTS: Genetics, Environment and Therapies: Food Allergy Clinical Tolerance Studies.   CIHR Programmatic Grants in Food and Health.  2013-18.  $1.5M           
  • B. Singh, V. Gerdts, & J.R. Gordon. Integrated Training Program (ITraP) for Infectious Diseases & Food Safety.  NSERC CREATE program.  2011-2016.  $4.6M (with matching funds)
  • S. Fowler, J. Jones, P. Hull and J.R. Gordon.  The immunological effects of extracorporeal photopheresis in Crohn’s Disease.  Royal University Hospital Foundation.  2012-13.  $20,000
  • M. Fenton & J.R. Gordon. Induction of transplant tolerance using IL-10-differentiated regulatory dendritic cells. Canadian Lung Association.  2012-14.  $60,000
  • B. Singh, D. Freeman, L. Martz, R. Buckingham, J.R. Gordon.  International Partnership Fund Program matching grant (Univ Saskatchewan/Guru Angad Dev Veterinary & Animal Sciences Univ, Ludhiana, India).  Partnership engagement infrastructure grant.  2010-13.   $300,000          
  • M. Fenton (& 6 co-applicants).  CIHR MPD (meetings) grant.  Planning workshop for spirometric evaluation of Canadian First Nations to establish normative values.  2010-11.  $9,970
  • J. Dosman, S. Abonyi, J. Episkenew, P. Pahwa (and 12 co-applicants).  CIHR Operating Grant.  Assess, Redress, Re-assess: Addressing Disparities in Respiratory Health among First Nations People.  2011-16.  $1.98M.